Merck Serono, Open Monoclonal Technology in OmniRat Deal
Merck Serono and Open Monoclonal Technology Expand Collaboration
Merck Serono acquires unlimited access to OmniRat human antibody platform
Darmstadt, Germany, October 28, 2013 – Merck Serono, the biopharmaceutical division of Merck, and Open Monoclonal Technology, Inc. (OMT), a leader in the genetic engineering of animals for development of human therapeutic antibodies, today announced the expansion of the collaboration agreement they entered into in June 2012. Under the terms of the agreement, Merck will make an upfront payment to secure unlimited access to the OmniRat ™ technology platform as well as success - based development milestones and royalties. Further details of the contract are not being disclosed.
“The expansion of our collaboration with OMT is reflective of its strong quality and the significant progress we've made to gether over the last 15 months,” said Dr. Annalisa Jenkins , Executive Vice Presidentand head of Global Research & Development for Merck Serono.“ This is a good example of our focus on exploring targeted partnerships with innovative companies such as OMT, with the
goal of generating access to technologies that advance our capabilities in biotech development. ”
Dr. Roland Buelow, founder and CEO of OMT, said: “ Merck’s transition to unlimited platform access is evidence of their success with OmniRat on multiple therapeutic targets during the past 15 months. The expansion illustrates how OMT provides its partners with access to complementary platforms for discovery of superior antibodies against challenging targets in a cost - effective fashion.”
About Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for development of human therapeutic antibodies – naturally optimized human antibodies . OMT has created OmniRat™ , the industry’s first fully human monoclonal antibody platform based on rats. The genetic engineering is the result of improved understanding of B cell development and a breakthrough
approach to inactivation of endogenous rat antibody expression. OmniRat represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies. Along
with Pfizer, OMT demonstrated that OmniRat animals have a complete immune system with a diverse antibody repertoire and generate antibodies with fully human idiotypes as well as wild - type animals make rat antibodies (Journal of Immunology 2013 Feb 15;190(4):1481 - 90).
OMT’s antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications and are presently partnered with companies such as Pfizer, Merck, Janssen, Symphogen, WuXi AppTec and other biopharmaceutical companies.
For more information, please visit www.omtinc.net
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis,
infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies
in our core focus areas of neurology, oncology, immunooncology and immunology.
+49 6151 72
Posted: October 2013